Anti-inflammatory treatment is the pharmacological cornerstone of asthma management. However, for a long time, short-acting beta-agonists (SABAs) have been proposed as rescue medications in all treatment steps and as monotherapy for milder asthma. This was based on the unproven assumption that symptom relief requires only bronchodilation. Herein, we describe the evolution of the Inhaled corticosteroid (ICS) Containing resCUE (IC-CUE; ICQ) algorithm by tracing its origins and projecting it into the future.

中文翻译：

---

ICQ 哮喘算法：吸入皮质类固醇救援 (ICQ) 治疗用于当前和未来的哮喘管理

抗炎治疗是哮喘治疗的药理学基础。然而，长期以来，短效 β 受体激动剂 (SABA) 已被提议作为所有治疗步骤中的抢救药物以及作为轻度哮喘的单一疗法。这是基于未经证实的假设，即症状缓解仅需要支气管扩张。在这里，我们通过追踪其起源并将其预测到未来来描述吸入性皮质类固醇 (ICS) 包含 resCUE (IC-CUE; ICQ ) 算法的演变。